WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018048943) CRYSTALLINE FORMS OF A LYSYL OXIDASE-LIKE 2 INHIBITOR AND METHODS OF MAKING
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/048943    International Application No.:    PCT/US2017/050332
Publication Date: 15.03.2018 International Filing Date: 06.09.2017
IPC:
C07D 401/12 (2006.01), A61K 31/4439 (2006.01)
Applicants: PHARMAKEA, INC. [US/US]; 3030 Bunker Hill Street, Suite 300 San Diego, California 92109 (US)
Inventors: LONERGAN, David; (US).
HOLME, Kevin Ross; (US).
ROWBOTTOM, Martin W.; (US)
Agent: ZUNIC, Valentin B.; (US)
Priority Data:
62/384,596 07.09.2016 US
Title (EN) CRYSTALLINE FORMS OF A LYSYL OXIDASE-LIKE 2 INHIBITOR AND METHODS OF MAKING
(FR) FORMES CRISTALLINES D'UN INHIBITEUR DE LYSYL OXYDASE DE TYPE 2 ET LEURS PROCÉDÉS DE FABRICATION
Abstract: front page image
(EN)Described herein are crystalline forms of pharmaceutically acceptable salts of the lysyl oxidase-like 2 (LOXL2) inhibitor (3-(4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yloxy)phenyl)((3R,4R)-3-fluoro-4-hydroxypyrrolidin-1-yl)methanone. Also described are methods of making the LOXL2 inhibitor, pharmaceutical compositions and medicaments comprising the LOXL2 inhibitor, and methods of using the LOXL2 inhibitor in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
(FR)L'invention concerne des formes cristallines de sels pharmaceutiquement acceptables de l'inhibiteur de la lysyl oxydase de type 2 (LOXL2) (3- (4- (aminométhyl)-6-(trifluorométhyl) pyridin-2-yloxy) phényl) ( (3R,4R)-3-fluoro-4-hydroxypyrrolidin-1-yl) méthanone. L'invention concerne également des procédés de fabrication de l'inhibiteur LOXL2, des compositions pharmaceutiques et des médicaments comprenant l'inhibiteur LOXL2, et des procédés d'utilisation de l'inhibiteur LOXL2 dans le traitement d'états, de maladies ou de troubles associés à l'activité LOXL2.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)